Sirtex Medical (ASX:SRX) saw shares tumble more than 25% today after a trial of its radioactive microspheres reported no effect in improving survival in patients with colorectal cancer. Results from the Foxfire analysis study indicated that the use of SIR-Spheres Y-90 microspheres in combination with chemotherapy did not improve overall survival in patients with unresectable colorectal […]
Sirtex Medical
Study: Sirtex’s microspheres improve quality of life, but don’t extend survival
Sirtex Medical (ASX:SRX) said today that it’s yttrium-90 resin microspheres did not extend survival significantly compared to Bayer’s sorafenib in a study of patients with hepatocellular carcinoma. Although the 459-patient trial did not meet its primary endpoint, the company reported that patients treated with its microspheres experienced less than half the number of severe, treatment-related […]
Sirtex Medical shares sink on shareholder suit
Sirtex Medical (ASX:SRX) shares fell this week after announcing it is facing a suit from shareholders alleging it breached continuous disclosure obligations and engaged in misleading and deceptive conduct. The Australian company said it has received a draft claim of the suit, which alleges that the double-digit growth outlook for dose sales for its fiscal year […]
National cancer group recommends Sirtex’s microspheres for metastatic colorectal cancer
Sirtex Medical (ASX:SRX) said yesterday that the National Comprehensive Cancer Network has recommended the company’s radioactive microspheres in its Clinical Practice Guidelines in Oncology for colon cancer and rectal cancer. The NCCN panel uniformly agreed that selective internal radiation therapy with yttrium-90 microspheres is an option for patients with metastatic, chemotherapy resistant colorectal cancer. The recommendation was […]
Sirtex slides on lowered profit outlook
Sirtex Medical (ASX:SRX) shares closed down more than -37% today after the Australian medical device company lowered its profit outlook for the rest of the year. Sydney-based Sirtex said it expects earnings before interest, taxes, depreciation and amortization to be down -12% on a constant-currency basis compared with fiscal 2016 for the year ending June 30, […]
Sirtex Medical jumps on surging sales, profits for fiscal 2016
By Sarah Faulkner Shares in Sirtex Medical (ASX:SRX) closed up nearly 12% today after the Australian medical device company posted huge boosts to both the bottom and top lines. Sydney-based Sirtex Medical makes targeted liver cancer therapies using resin microspheres called SIR-sphere Y-90. Sirtex said profits were $40.8 million (A$53.6 million), or 70¢ (A92.2¢) per share, on sales of […]
Sirtex jumps on higher-than-expected microsphere sales
Sirtex Medical today saw shares rise as much as 6.5% today after reporting higher than expected sales of its SIR-Spheres Y-90 resin microspheres for the 12 months ended June 30. That’s 16.4% up from last year, the Australian company reported, and between 15 and 17% higher than the guidance the company released on June 1st. […]
Sirtex slides on sales veep’s exit
SirTex Medical saw share prices fall as much as 7.2% to trade at $21.36 (AUD $28.10), the lowest it’s been in 9 months, after announcing today that its Americas prez Mike Mangano is set to leave at the end of the financial year. SirTex stock has lost 24.4% this year as of Thursday’s close, and […]
Can Sirtex turn cancer into a chronic disease?
Big things sometimes come in small packages. For Sirtex Medical, big things come in a really small package. The Australian medical device company’s flagship product – SIR-Spheres® Y-90 resin microspheres – is made up of 30 million to 60 million microspheres about the size of a grain of sand, which are injected into the hepatic artery and […]
Sirtex Medical Inc. Half-year Dose Sales Surge 28 Percent in Advance of SIRFLOX Primary Endpoint Announcement
WOBURN, Mass. (February 18, 2015) –Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), has announced that dose sales of SIR-Spheres(R) Y-90 resin microspheres in the Americas region grew more than 28 percent for the first half of the company’s fiscal year compared to the same period last year, with 3,390 doses supplied for the period July through December 2014. The gross sales in the region equate to $54.3M in the first half of the current fiscal year compared to $39.8M from the prior year, a 36.7% increase. Globally the company announced sales of 4,950 doses, an increase of 26.3% over the previous corresponding six-month period.
Sirtex Medical Inc. experiences record growth, expands business into Brazil
WOBURN, Mass. (September 8, 2014) –– Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), a leading manufacturer of targeted, liver cancer therapies, announced today the expansion of its business in Latin America. Sirtex’s SIR-Spheres® microspheres are now available to treat inoperable liver tumors in Brazil. The first SIR-Spheres microspheres treatments took place the first week of September at Hospital Sirio-Libanes in Sao Paulo. Sirtex received product approval from the Agência Nacional de Vigilância Sanitária (ANVISA) for SIR-Spheres microspheres early in 2014.